Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PBRM1 | Q86U86 | 11/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 6/20 | 0.39 |
| ▸ | DDB1 | Q16531 | 4/20 | 0.39 |
| ▸ | BTK | Q06187 | 2/20 | 0.37 |
| ▸ | SMARCA2 | P51531 | 7/20 | 0.36 |
| ▸ | SMARCA4 | P51532 | 7/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24917943 | 0.93 | PBRM1 (0.43) | PBRM1CRBNDDB1BTKSMARCA2 | |
| SCHEMBL24918256 | 0.89 | SMARCA2 (0.41) | PBRM1CRBNDDB1BTKSMARCA2 | |
| SCHEMBL24918381 | 0.88 | SMARCA2 (0.41) | PBRM1CRBNDDB1BTKSMARCA2 | |
| SCHEMBL23301121 | 0.84 | SMARCA2 (0.44) | PBRM1CRBNBTKSMARCA2SMARCA4 | |
| SCHEMBL23331900 | 0.82 | SMARCA2 (0.41) | PBRM1CRBNBTKSMARCA2SMARCA4 | |
| SCHEMBL24918202 | 0.82 | SMARCA2 (0.41) | PBRM1CRBNBTKSMARCA2SMARCA4 | |
| SCHEMBL24918272 | 0.81 | SMARCA2 (0.41) | PBRM1CRBNDDB1SMARCA2SMARCA4 | |
| SCHEMBL31103345 | 0.80 | DDB1 (0.58) | PBRM1CRBNDDB1SMARCA2SMARCA4 | |
| SCHEMBL31101226 | 0.79 | DDB1 (0.48) | PBRM1CRBNDDB1SMARCA2SMARCA4 | |
| SCHEMBL29942778 | 0.79 | PBRM1 (0.47) | PBRM1SMARCA2SMARCA4BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | C4 THERAPEUTICS, INC. | 2023-01-26 | — | — | US | disclosed |
| CN-114728936-A | Bifunctional compounds for the treatment of cancer | 豪夫迈·罗氏有限公司 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021083949-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230024096-A1 | BIFUNCTIONAL COMPOUNDS FOR THE TREATMENT OF CANCER | SMARCC1, SMARCC2, SMARCA2 | PBRM1 99/4885CRBN 358/4885DDB1 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.